1997; 336:919–22.
19. Bux-Gewehr I, Schmandt S, Zotz RB, Scharf RE, Roggendorf M. Longterm hepatitis C seroconversion in a blood donor. Transfusion 2001; 41:427.
20. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20:17–35.
21. Alter MJ, Margolis HS, Krawczynski K, et al. Natural history of community- acquired hepatitis C in the United States. N Engl J Med 1992; 327:1899–905.
22. Tobler LH, Stramer SL, Kleinman SH, Brodsky JP, Todd DS, Busch MP. Misclassification of HCV-viremic blood donors as indeterminate by RIBA 3.0 because of human superoxide dismutase reactivity. Transfusion 2001; 41:1625–6.
23. Vernelen K, Claeys H, Verhaert AH, Volckaerts A, Vermylen C. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994; 343:853.
24. Damen M, Zaaijer HL, Cuypers HT, Vrielink H, van der Poel CL, Reesink HW, Lelie PN. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995; 35:745–9.
25. Williams IT, Gretch D, Fleenor M, et al. Hepatitis C virus RNA concentration and chronic hepatitis in a cohort of patients followed after developing acute hepatitis C. In: Margolis HS, Alter MJ, Liang TJ, Dienstag JL, eds. Viral hepatitis and liver disease. Atlanta, GA: International Medical Press, 2002; 341–4.
26. Thomas DL, Astemborski J, Rai RM, et al. Natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450–6.
27. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002; 36:993–1000.
28. Tobler LH, Tegtmeier G, Stramer SL, et al. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000; 40:15–24.
29. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36:S93–S98.
30. Davis GL, Lau JY, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19:1337–41.